Published in Drug Week, October 27th, 2006
According to recent research published in the American Journal of Clinical Oncology - Cancer Clinical Trials, "[The study's aim was] to determine the MTD and dose limiting toxicities of poly(L-glutamic acid)-paclitaxel (PPX) and concurrent RT (PPX/RT) for patients with esophageal and gastric cancer. Patients with esophageal or gastric cancer receiving chemoradiation for loco-regional, adjuvant, or palliative intent were eligible. The initial dose of PPX was 40 mg/m2/wk, for 6...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.